Navnath S. Gavande earned his Ph.D. under the supervision of Prof. Mary Chebib (Collins) and Prof. Jane R. Hanrahan at The University of Sydney (Australia). Dr. Gavande has worked with distinguished Prof. Arun K. Ghosh as a postdoctoral fellow at Purdue University on several medicinal chemistry projects. The Ghosh laboratory developed Darunavir (Prezista®), an FDA-approved first-line drug treatment for drug-resistant HIV for HIV/AIDS patients. As a research assistant professor, he worked with Prof. John J. Turchi at the Indiana University School of Medicine. Dr. Gavande began his independent career as an assistant professor at the Eugene Applebaum College of Pharmacy and Health Sciences (EACPHS), Wayne State University, in 2019. He has since established a versatile drug discovery and development lab with expertise in computational chemistry/biology, synthetic/medicinal chemistry, biochemical and biophysical assays, molecular biology, cell biology, and animal studies. The research work in Gavande laboratory is supported by the National Institutes of Health (R01CA247370 and R01AI161570), the Department of Defense (W81XWH-22-1-0369), the VA, KCI’s Michigan SPORE, Richard Barber Interdisciplinary Research Program, DMC Foundation, WSU Applebaum Faculty Research Award (FRAP) and the Wayne State University.
Navnath S. Gavande earned his Ph.D. under the supervision of Prof. Mary Chebib (Collins) and Prof. Jane R. Hanrahan at The University of Sydney (Australia). Dr. Gavande has worked with distinguished Prof. Arun K. Ghosh as a postdoctoral fellow at Purdue University on several medicinal chemistry projects. The Ghosh laboratory developed Darunavir (Prezista®), an FDA-approved first-line drug treatment for drug-resistant HIV for HIV/AIDS patients. As a research assistant professor, he worked with Prof. John J. Turchi at the Indiana University School of Medicine. Dr. Gavande began his independent career as an assistant professor at the Eugene Applebaum College of Pharmacy and Health Sciences (EACPHS), Wayne State University, in 2019. He has since established a versatile drug discovery and development lab with expertise in computational chemistry/biology, synthetic/medicinal chemistry, biochemical and biophysical assays, molecular biology, cell biology, and animal studies. The research work in Gavande laboratory is supported by the National Institutes of Health (R01CA247370 and R01AI161570), the Department of Defense (W81XWH-22-1-0369), the VA, KCI’s Michigan SPORE, Richard Barber Interdisciplinary Research Program, DMC Foundation, WSU Applebaum Faculty Research Award (FRAP) and the Wayne State University.